IgG Anti-Cardiolipin Antibody (IgG ACL Antibody) - Immunoassay
This test measures the presence of antibodies against cardiolipin, a protein found in cell membranes, which may be linked to certain autoimmune conditions.
["Helps assess potential autoimmune or inflammatory conditions, including lupus or other connective tissue disorders."]
Key facts at a glance
- LOINC
- 48890-8
- Short code
- COXPH1M
- Synonyms
- C burnet Ph1 IgM Titr Fld IF
- Category
- chemistry
- Sample
- serum
- Container
- Serum separator tube (SST, tiger-top) or plain red-top tube; alternate: plasma from EDTA or heparin tube
- Units
- N/A
- Ref low
- 0
- Ref high
- 1
- Critical range
- — – 200 N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- ≥ 0 years
- Method
- Immunofluorescence assay (IFA) for detection of IgM antibodies directed against Phase 1 antigen of Coxiella burnetii
- CPT
- 86638
- SNOMED
- 12196007
- Specimen volume
- 1.0 mL serum (minimum 0.5 mL)
- Stability
- Stable for 7 days at 2–8°C; for extended storage, freeze at -20°C or below for up to 4 weeks. Avoid repeated freeze-thaw cycles.
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 500
- TAT
- 24–72 hours
- Order
- routine
What Is This Test Measuring?
Your blood sample is tested for IgG antibodies that target cardiolipin, a fatty acid-protein complex. These antibodies can be detected using an immunoassay method, which identifies their presence through a chemical reaction that produces a measurable signal.
Why Might This Test Be Ordered?
Doctors may order this test if you have symptoms suggestive of autoimmune diseases, such as joint pain, unexplained fatigue, or a history of blood clots or lupus. It can also be part of a broader evaluation for conditions like antiphospholipid syndrome.
Sample Collection and Preparation
A blood sample is drawn from a vein in your arm. The sample is processed to separate serum (the liquid part of blood without clotting factors) for testing. This test does not require fasting.
What Does a Positive Result Mean?
A positive result indicates the presence of IgG antibodies against cardiolipin, which may suggest an autoimmune response. However, this alone does not diagnose a specific condition; further clinical correlation and testing are needed.
Reference range
Titer <1:50: Negative – no detectable Phase 1 IgM antibodies; Titer 1:50–1:100: Equivocal/borderline – recommend repeat testing in 2–4 weeks; Titer ≥1:200: Positive – suggests recent or acute Q fever infection, particularly indicative of chronic Q fever (e.g., endocarditis, vascular infection) when Phase 1 IgG titers are also elevatedN/A
No fasting required. Patient should be informed that this test detects antibodies to Coxiella burnetii, the causative agent of Q fever. A second (convalescent) specimen collected 2–4 weeks after the acute specimen is strongly recommended to demonstrate seroconversion or rising titers for accurate diagnosis.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
◆Associated findings1
Short name
IgG ACL Antibody
Frequently asked questions
What does a positive result mean for my health?
How often should I get this test?
Can lifestyle changes affect this test result?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy